HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consumer genetic tests

This article was originally published in The Tan Sheet

Executive Summary

A July 31 FDA consumer alert advises that at-home genetic tests "may lack scientific validity or provide meaningful results only in the context of a full medical evaluation." The Government Accountability Office recently issued a report evaluating the genetic tests and found some made disease-risk claims and offered dietary advice that "rarely goes beyond standard sensible dietary recommendations" (1"The Tan Sheet" July 31, 2006, p. 9). The Federal Trade Commission also recently reminded consumers that "because of the complexities involved in both the testing and the interpretation of the results, genetic tests should be performed in a specialized laboratory, and the results should be interpreted by a doctor or trained counselor"...

You may also be interested in...



GAO Report, FTC Warn Consumers Of Misleading At-Home Genetic Kits

The validity of at-home genetic tests has come under fire from both the Federal Trade Commission and the Government Accountability Office

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

BMS Has A Strong Pipeline, But Access Challenges Remain

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS125753

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel